Regenerative Medicine Markets

Product Code TRI00113
Publication Date September 2010
Publisher TriMark Publications
Product Type Report
Pages 288
ISBN Number not applicable
Change currency
PDF £2,150.00 €2,589 $3,400 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

Regenerative Medicine Markets

Regenerative medicine is a way of treating injured and diseased human tissue by using laboratory-grown or therapeutically-induced human tissue as a replacement. As such, astounding new advancements in the ability to repair or replace damaged human tissue and organ functions are being made. Whereas before, remedies for damaged tissue or organ functions due to congenital deformities, injuries, diseases or simple wear-and-tear relied upon either the body's ability to repair itself (or not), or a surgeon's skilled hands. Now, the area of regenerative medicine promises to revolutionize humanity's ability to remediate countless physical maladies that have perpetually afflicted humans and other animals. Compared to a select few life forms--like the starfish--man-made solutions for tissue repair and organ replacement haven't come close to nature's solutions. And where there once was no solution even offered by nature, researchers are now at the cusp of overcoming such limitations by literally regrowing damaged tissue and restoring organ functions through the use of tissue engineering and stem cell therapy. This is the promise of regenerative medicine.

This TriMark Publications report discusses the current state of regenerative medicine. The study provides a thorough overview of regenerative medicine sector together with analyses of the funding trends, intellectual property, market opportunities, therapeutic pipeline, research collaborations, partnership activities, and guidelines for establishing new ventures.

The report enables the reader gain in-depth knowledge about ongoing tissue engineering and stem cell therapy research programs carried out in universities and other research centers. Moreover, this analysis profiles the leading companies developing regenerative medicine solutions.

Contents

  • 1. Overview
    • 1.1 Statement of Report
    • 1.2 Scope of this Report
    • 1.3 Methodology
    • 1.4 Executive Summary
  • 2. Regenerative Medicine: An Overview of Segments
    • 2.1 Tissue Engineering
      • 2.1.1 Tissue-Engineered Skin
      • 2.1.2 Tissue-Engineered Cartilage
      • 2.1.3 Tissue-Engineered Bone
      • 2.1.4 Tissue-Engineered Peripheral Nerves
      • 2.1.5 Tissue-Engineered Cornea
      • 2.1.6 Tissue-Engineered Blood Vessels
    • 2.2 An Overview of Tissue Engineering and Regenerative Medicine (TERM)
      • 2.2.1 Tissue-Engineered Products and Their Applications
        • 2.2.1.1 Skin, Cartilage, Bone and Urological Applications
        • 2.2.1.2 Cardiovascular Applications
        • 2.2.1.3 Neurological Applications
        • 2.2.1.4 Pancreas, Liver and Kidney Applications
        • 2.2.1.5 Ophthalmic Applications
        • 2.2.1.6 Dental Applications
        • 2.2.1.7 Autologous and Allogeneic Products
      • 2.2.2 Geographic Distribution of TERM Firms in the Five Focus Countries
    • 2.3 Cell Therapy
      • 2.3.1 Number of Patients Treated between 1988 and 2010 by Regenerative Medicine Therapies
      • 2.3.2 Cell Culture Products
        • 2.3.2.1 In vitro Test Kits
        • 2.3.2.2 Suppliers of Cells and Tissues
        • 2.3.2.3 Suppliers of Culture Media and Reagents
        • 2.3.2.4 Equipments for Stem Cell Research
        • 2.3.2.5 Computer Software for Stem Cell Research
      • 2.3.3 Overall Picture of Cell Therapy Industry
        • 2.3.3.1 The Size of Cell Therapy Industry
        • 2.3.3.2 The Age, Size and Location of Firms
        • 2.3.3.3 Technology and Disease Focus
      • 2.3.4 Cell Therapy Products and Companies
        • 2.3.4.1 First Generation (Non-Stem Cell-based) Primary Products
        • 2.3.4.2 Second Generation (Stem Cell-based) Primary Products
        • 2.3.4.3 Secondary Products
        • 2.3.4.4 Products in Development
      • 2.3.5 The Disease Focus of Clinical Trials
        • 2.3.5.1 Stem Cell Industry Pipeline
      • 2.3.6 Industry Collaboration in Stem Cell Space
        • 2.3.6.1 Commercial Success in Stem Cell Industry
        • 2.3.6.2 Major Shift to Stem Cells from Non-Stem Cell Technologies
        • 2.3.6.3 Challenges to Commercial Development of Cell Therapies
        • 2.3.6.4 Partnership of Stem Cell Companies with Large Pharmaceutical Companies
        • 2.3.6.5 Strategic Approaches for Cell-based Companies
        • 2.3.6.6 The Need for Support from Large Pharmaceuticals
    • 2.4 Scaffolding Biomaterials
      • 2.4.1 Biomaterial Scaffolds in Regenerative Medicine
    • 2.5 Growth Factors
  • 3. Regenerative Medicine: The Next Evolution of Medical Treatments
    • 3.1 Scope of this Chapter
    • 3.2 Need for Regenerative Medicine
    • 3.3 Current State of Regenerative Medicine
    • 3.4 Future of Regenerative Medicine
    • 3.5 Number of Products in Pipeline
    • 3.6 Projected Timeline for Regenerative Medicine
    • 3.7 Regenerative Medicine Products in the Market
      • 3.7.1 Medtronic's Infuse Bone Graft and the LT-Cage Device
      • 3.7.2 Genzyme's Carticel
      • 3.7.3 Stryker's OP-1
      • 3.7.4 Osyris/Nuvasive's Osteocel
      • 3.7.5 RTI's Spinal Implants
      • 3.7.6 Organogenesis' Apligraf
      • 3.7.7 Advanced BioHealing's Dermagraft
      • 3.7.8 Integra's Bilayer Matrix Wound Dressing
      • 3.7.9 LifeCell's Alloderm
      • 3.7.10 Cytori Therapeutics' Celution
    • 3.8 Other Products of Importance in Regenerative Medicine
      • 3.8.1 Tissue-Engineered Wound Healing Products
        • 3.8.1.1 Oasis
        • 3.8.1.2 Permacol
        • 3.8.1.3 EZ-Derm
        • 3.8.1.4 Matriderm
        • 3.8.1.5 TransCyte
        • 3.8.1.6 ICX-SKN
        • 3.8.1.7 OrCel
        • 3.8.1.8 Epicel
        • 3.8.1.9 Myskin
        • 3.8.1.10 VCT01
      • 3.8.2 ICX-TRC-Hair Regeneration Therapy
      • 3.8.3 Cartilage Regeneration
        • 3.8.3.1 Novocart
        • 3.8.3.2 BioSeed-C
        • 3.8.3.3 BioSeed-Oral Bone
        • 3.8.3.4 Chondrotissue
        • 3.8.3.5 co.don Chondrotransplant
        • 3.8.3.6 co.don Chondrotransplant DISC
        • 3.8.3.7 co.don Chondrosphere
        • 3.8.3.8 co.don Osteotransplant DENT
        • 3.8.3.9 MACI Implant
        • 3.8.3.10 Cartilink-3
        • 3.8.3.11 Accell Evo3 Demineralized Bone Matrix
        • 3.8.3.12 OsSatura BCP
      • 3.8.4 Mozobil
  • 4. Market Analysis of Regenerative Medicine Sector
    • 4.1 Scope of this Chapter
      • 4.1.1 Market for Regenerative Medicine Products
      • 4.1.2 The Different Characteristics of Regenerative Medicine Industry in the Recent Past
      • 4.1.3 Potential Market for Regenerative Medicine in the U.S
    • 4.2 Global Market for Stem Cells
    • 4.3 Market for Cell Therapy in the U.S
    • 4.4 Global Market for Cord Blood Stem Cells
      • 4.4.1 Public Cord Blood Banks
      • 4.4.2 Private Cord Blood Banks
  • 5. Business Models and Requirements for a Successful Regenerative Medicine Industry
    • 5.1 Scope of this Chapter
      • 5.1.1 The Limited Success Achieved by the Regenerative Medicine Products
      • 5.1.2 Business Models in Regenerative Medicine
      • 5.1.3 Current Model for Autologous Cell Therapies
      • 5.1.4 Current Models for Allogeneic Cell Therapies
      • 5.1.5 Key Factors for Successful Business Models for Cell Therapies
    • 5.2 Commercial Manufacturing of Cell Therapy Products: Requirements
      • 5.2.1 Elements of Commercial Manufacturing
        • 5.2.1.1 Regulatory Requirements
        • 5.2.1.2 Manufacturing Process Scale
        • 5.2.1.3 In-House Manufacturing
        • 5.2.1.4 Contract Manufacturing: Commercial and Academic
  • 6. Diseases with Potential Applications for Regenerative Medicine
    • 6.1 Regenerative Medicine and Diabetes
    • 6.2 Regenerative Medicine for Cardiac Repair
    • 6.3 Regenerative Medicine in Orthopedics
      • 6.3.1 Orthobiologics in Orthopedics
      • 6.3.2 Growth Factor Therapies in Orthopedics
      • 6.3.3 Stem Cell Therapies in Orthopedics
    • 6.4 Regenerative Medicine in Liver Diseases
      • 6.4.1 Hepatocyte-like Cells for Liver Disease
      • 6.4.2 Cell Therapy for Liver Cirrhosis
      • 6.4.3 CD 34+ Cells
    • 6.5 Regenerative Medicine in Retinal Replacement Therapy
      • 6.5.1 Retinal Transplantation
    • 6.6 Regenerative Medicine in Central Nervous System (CNS) Disorders
      • 6.6.1 Clinical Activity for Stem Cell Transplantation into the CNS
  • 7. Current Stem Cell Research and Federal Funding in the U.S
    • 7.1 Scope of this Chapter
    • 7.2 Stem Cell Policies in North America
    • 7.3 Stem Cell Policies in South America
    • 7.4 Stem Cell Policies in Europe
    • 7.5 Stem Cell Policies in Asia/Oceania
    • 7.6 Stem Cell Policies in Africa
    • 7.7 Stem Cell Research and California Institute for Regenerative Medicine (CIRM)
      • 7.7.1 CIRM Collaborative Funding
      • 7.7.2 CIRM's funding for Clinical Applications
      • 7.7.3 Early Translational Awards
      • 7.7.4 CIRM's Disease Team Awards
    • 7.8 Stem Cell Research Programs in Connecticut Department of Public Health
      • 7.8.1 Seed Grant Awards from Connecticut Stem Cell Research Program in 2010
      • 7.8.2 Established Investigator Awards from Connecticut Stem Cell Research Program in 2010
      • 7.8.3 Group Project Awards from Connecticut Stem Cell Research Program in 2010
      • 7.8.4 Core Facility Awards from Connecticut Stem Cell Research Program in 2010
      • 7.8.5 Maryland Technology Development Corporation (TEDCO)
      • 7.8.6 TEDCO's Fort Detrick Technology Transfer Initiative (FDTTI)
      • 7.8.7 J&J Investment Fund
      • 7.8.8 TEDCO's NAVAIR Technology Insertion (NAVTI) Program
      • 7.8.9 TEDCO's TechStart Program
      • 7.8.10 TEDCO's University Technology Development Fund (UTDF)
      • 7.8.11 TEDCO's Working Capital Loan Fund
      • 7.8.12 Maryland Technology Transfer and Commercialization Fund (MTTCF)
      • 7.8.13 Maryland Stem Cell Research Fund
    • 7.9 The New Jersey Commission on Science and Technology (NJCST)
      • 7.9.1 Investigator Initiated Research Projects and Innovative (IIRP), Developmental or Exploratory Activities (IDEA) in Stem Cell Research
      • 7.9.2 Targeted RFA for Investigation of iPS and Other Derivation Approaches
      • 7.9.3 Shared Facilities/Resources and Equipment/Instrumentation for Stem Cell Research
      • 7.9.4 Consortia Planning Awards
      • 7.9.5 Institutional Development
    • 7.10 Center for Stem Cell and Regenerative Medicine
    • 7.11 Global Funding for Regenerative Medicine
    • 7.12 Federal Funding of Stem Cell Research in the U.S.: Past and Present
      • 7.12.1 The U.S. National Institute of Health (NIH) Guidelines to hESC Research
      • 7.12.2 Types of Research Ineligible for NIH Funding
      • 7.12.3 NIH's Leadership in Providing Funds for Stem Cell Research
      • 7.12.4 NIH Guidelines Addressing the Projected Growth of Stem Cell-related Clinical Trials
      • 7.12.5 Federal Agencies Providing Funds for Stem Cell Research
  • 8. Company Profiles
    • 8.1 Aastrom Biosciences, Inc
      • 8.1.1 Aastrom's Clinical Trial Programs
        • 8.1.1.1 Dilated Cardiomyopathy
        • 8.1.1.2 Critical Limb Ischemia
        • 8.1.1.3 Osteonecrosis of the Femoral Head
        • 8.1.1.4 Other Bone Disorders
      • 8.1.2 Product Development
      • 8.1.3 Aastrom's Cell Manufacturing
      • 8.1.4 Aastrom's Business Performance
    • 8.2 Advanced Cell Technology, Inc. (ACT)
      • 8.2.1 ACT's Cellular Reprogramming
      • 8.2.2 ACT's Stem Cell Differentiation
        • 8.2.2.1 ACT's Retinal Pigment Epithelium Program
        • 8.2.2.2 ACT's Hemangioblast Program
        • 8.2.2.3 ACT's Adult Stem Cell Program
      • 8.2.3 ACT's Intellectual Property
      • 8.2.4 ACT's Business Performance
      • 8.2.5 ACT's Investment in Research and Development
    • 8.3 Aldagen, Inc
      • 8.3.1 Aldagen's ALD-201
      • 8.3.2 Aldagen's ALD-301
    • 8.4 Altrika Ltd
      • 8.4.1 Myskin
      • 8.4.2 Cryoskin
      • 8.4.3 Altrika's Future Products
        • 8.4.3.1 Lyphoderm
        • 8.4.3.2 Corneal Bandage
        • 8.4.3.3 Leukodepletion Filters
    • 8.5 Alseres Pharmaceuticals, Inc
      • 8.5.1 Alseres' Product Pipeline
        • 8.5.1.1 Celthrin-a Rho Inhibitor
        • 8.5.1.2 Inosine
        • 8.5.1.3 Oncomodulin and ALSE-100
        • 8.5.1.4 Altropane-PD
      • 8.5.2 Alseres' Science and Technology
        • 8.5.2.1 Nerve Repair Pathways
        • 8.5.2.2 The Pro-Regenerative Pathway
        • 8.5.2.3 The Anti-Regenerative Pathway
        • 8.5.2.4 Molecular Imaging
        • 8.5.2.5 Dopamine Transporter
    • 8.6 Amgen, Inc
      • 8.6.1 Amgen's Marketed Products
        • 8.6.1.1 Aranesp (Darbepoetin Alfa)
        • 8.6.1.2 Epogen (Epoetin Alfa)
        • 8.6.1.3 Neulasta (Pegfilgrastim)/Neupogen (Filgrastim)
        • 8.6.1.4 Enbrel (Etanercept)
        • 8.6.1.5 Sensipar (cinacalcet)
        • 8.6.1.6 Vectibix (Panitumumab)
        • 8.6.1.7 Nplate (Romiplostim)
      • 8.6.2 Amgen's Marketing and Distribution
      • 8.6.3 Amgen's Overall Business Performance
    • 8.7 Amorcyte, Inc
      • 8.7.1 Amorcyte's Technology
        • 8.7.1.1 AMR-001
    • 8.8 AnGes MG, Inc
      • 8.8.1 AnGes' Genetic Medicine
      • 8.8.2 HGF Genetic Medicine
      • 8.8.3 Hemagglutinating Virus of Japan (HVJ) Envelope Vector
      • 8.8.4 NF kB Decoy Oligodeoxynucleotide
    • 8.9 Angioblast Systems, Inc
      • 8.9.1 Angioblast's Technology and Applications
        • 8.9.1.1 Allogenic Adult Stem Cells
        • 8.9.1.2 Protein Therapeutics
        • 8.9.1.3 Gene Slicing
    • 8.10 Angion Biomedica, Corp
      • 8.10.1 HGF and c-Met Signaling in Tissue Repair and Organ Regeneration
      • 8.10.2 PARP-1
      • 8.10.3 TGF B1
    • 8.11 Ars Arthro Biotechnology, Inc
      • 8.11.1 CaReS
      • 8.11.2 Fibrocell
      • 8.11.3 Fibroplus
    • 8.12 Arteriocyte Medical Systems, Inc
      • 8.12.1 Blood Pharming
      • 8.12.2 Cardiac Ischemia
      • 8.12.3 Critical Limb Ischemia
      • 8.12.4 Malaria Research
      • 8.12.5 Orthopedic Regenerative Medicine
      • 8.12.6 Proliferative Diabetic Retinopathy
      • 8.12.7 Wound Healing
    • 8.13 Athersys, Inc
      • 8.13.1 Athersys' Pipeline
      • 8.13.2 MultiStem for Stem Cell Therapy
      • 8.13.3 MultiStem for BM Transport Support
      • 8.13.4 MultiStem for Acute Myocardial Infarction
      • 8.13.5 MeriStem for Stroke
      • 8.13.6 Treatments for Obesity
      • 8.13.7 Histamine H3 Receptor Antagonists
      • 8.13.8 Athersys' Collaborations and Partnerships
        • 8.13.8.1 Collaboration with Pfizer
        • 8.13.8.2 Collaboration with Angiotech
        • 8.13.8.3 Collaboration with Bristol-Myers Squibb
      • 8.13.9 Athersys' Research and Development
      • 8.13.10 Athersys' Business Performance
    • 8.14 BeFutur Biotechnologies
      • 8.14.1 BeFutur's Technologies
        • 8.14.1.1 Cells and Tissue Engineering
        • 8.14.1.2 Serum Free Technology
    • 8.15 BioE, Inc
      • 8.15.1 BioE's Products
    • 8.16 Bioheart, Inc
      • 8.16.1 Bioheart's Product Candidates
        • 8.16.1.1 MyoCell
        • 8.16.1.2 MyoCell SDF-1
        • 8.16.1.3 TGI 1200 Cell Isolation System
        • 8.16.1.4 Bioheart 3370
      • 8.16.2 Bioheart's Patents and Proprietary Rights
    • 8.17 BioLine Rx
      • 8.17.1 BioLine's Product Pipeline
        • 8.17.1.1 BL-1020 Schizophrenia
        • 8.17.1.2 BL-1040 for Acute Myocardial Infarction
        • 8.17.1.3 BL-5010 for Skin Lesions
        • 8.17.1.4 BL-1021 for Neuropathic Pain
        • 8.17.1.5 BL-2030 for Inflammation
        • 8.17.1.6 BL-1023 for Parkinson's disease
        • 8.17.1.7 BL-4010 for Cancer
        • 8.17.1.8 BL-4040 for Acute Kidney Failure
        • 8.17.1.9 BL-5030 for Thromboembolic Diseases
        • 8.17.1.10 BL-5040 for Cachexia and Inflammatory Bowel Disease
    • 8.18 BIOMET
      • 8.18.1 BIOMET 3i
      • 8.18.2 Clotalyst Autologous Serum Collection System
      • 8.18.3 BioCUE Platelet Concentration System
    • 8.19 BioMimetic Therapeutics, Inc
      • 8.19.1 BioMimetic's Product Candidates
      • 8.19.2 BioMimetic's Research and Development
    • 8.20 BioSafe Group SA
      • 8.20.1 Sepax
      • 8.20.2 Sepax System in Adult Stem Cell Banking
      • 8.20.3 Coolmix
      • 8.20.4 SepaxNet
    • 8.21 BioTime, Inc
      • 8.21.1 BioTime's Stem Cell Products for Regenerative Medicine
      • 8.21.2 BioTime's Embryome Database
      • 8.21.3 BioTime's Progenitor and hES Cell Lines
      • 8.21.4 BioTime's hES Cells Carrying Genetic Diseases
      • 8.21.5 BioTime's ESpan Cell Growth Media
      • 8.21.6 BioTime's ESpy Cell Lines
      • 8.21.7 BioTime's Licensed Stem Cell Technology and Stem Cell Product Development Agreements
        • 8.21.7.1 Wisconsin Alumni Research Foundation
        • 8.21.7.2 ACTCellerate Technology
        • 8.21.7.3 The iPS Technology
        • 8.21.7.4 Lifeline
        • 8.21.7.5 BioTime's Stem Cell Agreement with Reproductive Genetics Institute
      • 8.21.8 BioTime's Plasma Volume Expanders and Related Products
        • 8.21.8.1 Hextend
        • 8.21.8.2 PentaLyte
    • 8.22 Biovest International, Inc
      • 8.22.1 BiovaxID Cancer Vaccine
    • 8.23 BrainStorm Cell Therapeutics, Inc
      • 8.23.1 BrainStorm's Technology
      • 8.23.2 BrainStorm's Stem Cell Therapy
      • 8.23.3 BrainStorm Technology-NurOwn
    • 8.24 Cardio3 BioSciences
      • 8.24.1 Cardio3's Product Pipeline
        • 8.24.1.1 C-Cure
        • 8.24.1.2 C-Cure2
        • 8.24.1.3 Allo-Cure
        • 8.24.1.4 G-Cure
        • 8.24.1.5 C-Cath
      • 8.24.2 Cardio3's Investors
    • 8.25 CardioPolymers, Inc
      • 8.25.1 CardioPolymer's Products
        • 8.25.1.1 Algisyl-LVR
        • 8.25.1.2 Plexisyl-AF
      • 8.25.2 CardioPolymer's Investors
    • 8.26 CaridianBCT
      • 8.26.1 Trima Accel Automated Blood Collection System
      • 8.26.2 Spectra Optia Apheresis System
      • 8.26.3 COBE Spectra Apheresis System
      • 8.26.4 Elutra Cell Separation System
      • 8.26.5 Atreus Whole Blood Processing System
      • 8.26.6 OrbiSac System
      • 8.26.7 COBE 2991 Cell Processor
    • 8.27 Cardium Therapeutics, Inc
      • 8.27.1 Cardium Biologics
      • 8.27.2 Cardium's Tissue Repair Company
      • 8.27.3 Cardium's Gene Activated Matrix (GAM) Technology
      • 8.27.4 Cardium's Biologics and Stem Cells for Regenerative Medicine
    • 8.28 Cellartis AB
      • 8.28.1 Cellartis' Products
        • 8.28.1.1 The hES-CMC 2D: Cardiomyocyte Monolayers
        • 8.28.1.2 The hES-CMC 002: Cardiomyocyte Clusters
        • 8.28.1.3 The hES-HEO 002: Hepatocyte-like Cells
        • 8.28.1.4 The hES-MP 002.5: Mesenchymal Progenitors
        • 8.28.1.5 The hES Cell Lines
        • 8.28.1.6 SCED 461: Human ES Cells
        • 8.28.1.7 Monoclonal Antibodies
      • 8.28.2 Cellartis' Licensing Activities
    • 8.29 Cellerix
      • 8.29.1 Ontaril
      • 8.29.2 Cx501
    • 8.30 Celgene Corporation
      • 8.30.1 Celgene's Business Performance
      • 8.30.2 Celgene's Commercial Stage Products
        • 8.30.2.1 Revlimid (Lenalidomide)
        • 8.30.2.2 Thalomid (Thalidomide)
        • 8.30.2.3 Vidaza (Azacitidine for Injection)
        • 8.30.2.4 Ritalin Family of Drugs
        • 8.30.2.5 Alkeran (Melphalan)
        • 8.30.2.6 IMiDs Compounds
        • 8.30.2.7 Oral Anti-Inflammatory Agents
        • 8.30.2.8 Kinase Inhibitors
        • 8.30.2.9 Cellular Therapies
    • 8.31 CellSeed, Inc
      • 8.31.1 CellSeed's Epithelial Cell Sheet for Corneal Regeneration
      • 8.31.2 CellSeed's Regenerated Cardiac Patch
      • 8.31.3 CellSeed's Epithelial Cell Sheet for Esophageal Regeneration
      • 8.31.4 CellSeed's Cell Sheet for Periodontal Tissue Regeneration
      • 8.31.5 CellSeed's Regenerated Cartilage Sheet
    • 8.32 Cellular Dynamics International
      • 8.32.1 The iCell Cardiomyocytes
      • 8.32.2 Cellular Dynamics' Technology
    • 8.33 Celltrix
      • 8.33.1 Credurance
    • 8.34 Cerco Medical
      • 8.34.1 Cerco Medical's Concept
      • 8.34.2 Bio-artificial Endocrine Pancreas
    • 8.35 Cook Biotech, Inc
      • 8.35.1 Cook's Technology
      • 8.35.2 Biodesign Dural Graft
      • 8.35.3 Dynamatrix Oral Graft
      • 8.35.4 SiS Ophthalmic
      • 8.35.5 Oasis Wound Matrix
      • 8.35.6 Biodesign Staple Line Reinforcement
      • 8.35.7 Biodesign Hiatal Hernia Graft
      • 8.35.8 ECM for Pericardial Closure
      • 8.35.9 ECM for Cardiac Tissue Repair
      • 8.35.10 Biodesign 8-Layer Tissue Graft
      • 8.35.11 Biodesign Abdominal Lock Graft
      • 8.35.12 Biodesign Hernia Graft
      • 8.35.13 Biodesign Inguinal Hernia Graft
      • 8.35.14 Biodesign Umbilical Hernia Graft
      • 8.35.15 Biodesign Anterior Pelvic Floor Graft
      • 8.35.16 Biodesign Fistula Plug
      • 8.35.17 Biodesign Posterior Pelvic Floor Graft
      • 8.35.18 Surgisis Biodesign Peyronie's Repair Graft
      • 8.35.19 Biodesign Tension-free Urethral Sling
      • 8.35.20 Biodesign Vaginal Erosion Repair Graft
      • 8.35.21 AxoGuard Nerve Protector
      • 8.35.22 AxoGuard Nerve Connector
      • 8.35.23 FISH Femoral Introducer Sheath and Hemostasis Device
    • 8.36 Cord Blood America (CBAI), Inc
    • 8.37 Cryo-Cell International, Inc
      • 8.37.1 Cryo Cell's License Agreements
      • 8.37.1.l Cryo-Cell De Mexico
        • 8.37.1.2 Asia Cryo-Cell Private Limited
        • 8.37.1.3 Venezuela
        • 8.37.1.4 China
        • 8.37.1.5 Germany
        • 8.37.1.6 Nicaragua
        • 8.37.1.7 Pakistan
      • 8.37.2 Uses of Cord Blood Stem Cells
    • 8.38 Curis, Inc
      • 8.38.1 Curis' Business Performance
      • 8.38.2 Curis' Research and Development
    • 8.39 Cytori Therapeutics, Inc
      • 8.39.1 Cytori's Cosmetic and Reconstructive Surgery Market
      • 8.39.2 Cytori StenSource Cell Banking Market
    • 8.40 Develogen AG
      • 8.40.1 Develogen's Pipeline
        • 8.40.1.1 DG3173-Somatostatin Analog
        • 8.40.1.2 Insulin Sensitizers
        • 8.40.1.3 Beta Cell Regeneration Factor
    • 8.41 Effector Cell Institute, Inc (ECI)
      • 8.41.1 ECI's Cell-based Drug Discovery (CDD)
      • 8.41.2 ECI's Regenerative Medicine
      • 8.41.3 ECI's Cancer Therapeutic Agent Development Project (EC1301)
      • 8.41.4 ECI's Anti-Inflammatory Drug Development Project (FROUNT)
      • 8.41.5 ECI's High Throughput Screening by Automatic TAXIScan System
      • 8.41.6 ECI's Products
        • 8.41.6.1 TAXIScan System
        • 8.41.6.2 Cytorecon
        • 8.41.6.3 TAXIScan-FL
    • 8.42 Epistem plc
      • 8.42.1 Epistem's Cotract Research Services in Oncology
      • 8.42.2 Epistem's Xenografting Models
      • 8.42.3 Epistem's Cancer Cell Assays
      • 8.42.4 Epistem's Angiogenesis Models
      • 8.42.5 Epistem's Colon Cancer Models (Min/+)
      • 8.42.6 Epistem's Histology, IHC, ISH and Gene Expression Profiling
      • 8.42.7 Epistem's In vitro Cytotoxicity Testing
      • 8.42.8 Epistem's Plucked Hair Immunohistochemistry
      • 8.42.9 Epistem's Emerging Protein Therapeutics
      • 8.42.10 Epistem's Biomarker Technology
    • 8.43 FivePrime Therapeutics, Inc
      • 8.43.1 FivePrime's Technology
      • 8.43.2 FivePrime's Collaborations
    • 8.44 Forticell Bioscience, Inc
      • 8.44.1 OrCell
    • 8.45 Gamidia Cell Ltd
      • 8.45.1 Gamidia's Technology
    • 8.46 GeneGrafts Ltd
      • 8.46.1 Gene Graft's Technology
    • 8.47 GenVec, Inc
      • 8.47.1 GenVec's Product Programs
        • 8.47.1.1 TNFerade
        • 8.47.1.2 Hearing and Balance
    • 8.48 Genzyme Corporation
      • 8.48.1 Genzyme's Business Performance
      • 8.48.2 Genzyme's Genetic Diseases Segment
      • 8.48.3 Genzyme's Hematology Oncology Segment
      • 8.48.4 Genzyme's Cardiometabolic and Renal Segment
      • 8.48.5 Genzyme's Biosurgery Segment
      • 8.48.6 Genzyme's Genetics and Diagnostics Segment
      • 8.48.7 Genzyme's Pipeline
    • 8.49 Geron Corporation
      • 8.49.1 Geron's Major Technology Platforms
        • 8.49.1.1 Role of Telomere in Cancer and Aging
        • 8.49.1.2 Human Embryonic Stem Cells: Source for the Manufacturing of Therapeutic Cells
      • 8.49.2 Commercial Opportunities for Geron's Major Technology Platforms
        • 8.49.2.1 Oncology
      • 8.49.3 Geron's Human Embryonic Stem Cell Therapies
      • 8.49.4 Geron's Patents and Proprietary Technology
      • 8.49.5 Geron's Business Performance
      • 8.49.6 Geron's Investment in Research and Development
    • 8.50 Harvest Technologies Corporation
      • 8.50.1 Harvest Technologies' Products
        • 8.50.1.1 SmartPReP2 APC+
        • 8.50.1.2 SmartPReP 2 BMAC
    • 8.51 HemaStem Therapeutics, Inc
      • 8.51.1 Cord Blood Program
    • 8.52 HepaLife Technologies, Inc
      • 8.52.1 Liver Disease
        • 8.52.1.1 HepaMate
    • 8.53 Humacyte, Inc
      • 8.53.1 Humacyte's Products
    • 8.54 Hydra Biosciences, Inc
      • 8.54.1 Hydra's Program
    • 8.55 Intercytex Group plc
      • 8.55.1 Vavelta-Skin Repair and Rejuvenation
      • 8.55.2 SHEF-1-Stem Cell Line
      • 8.55.3 CX-SKN-Skin Graft Replacement for Burns and Acute Wounds
      • 8.55.4 ICX-TRC-Hair Regeneration
      • 8.55.5 Cyzact-Chronic Wound Repair
    • 8.56 Integra Lifesciences Holdings Corporation
      • 8.56.1 Integra's Products
        • 8.56.1.1 Integra's Orthopedic Product Portfolio
        • 8.56.1.2 Dermal Regeneration and Engineered Wound Dressings
        • 8.56.1.3 Nerve and Tendon
        • 8.56.1.4 Bone Graft Substitutes for Extremity Reconstruction
        • 8.56.1.5 Integra's OrthoBiologics
        • 8.56.1.6 Duraplasty Products
      • 8.56.2 Integra's Investment in Research and Development
      • 8.56.3 Integra's Business Performance
    • 8.57 International Stem Cell Corporation (ISCO)
      • 8.57.1 Lifeline Cell Technology
      • 8.57.2 Universal Stem Cell Bank
      • 8.57.3 ISCO's Technology
    • 8.58 Japan Tissue Engineering, Co., Ltd
      • 8.58.1 Autologous Cultured Epidermis
      • 8.58.2 Autologous Cultured Cartilage
      • 8.58.3 Autologous Cultured Corneal Epithelium
    • 8.59 Karocell Tissue Engineering AB
      • 8.59.1 Karocell's Autologous Cells
        • 8.59.1.1 Keratinocytes
        • 8.59.1.2 Melanocytes
        • 8.59.1.3 Fibroblasts
        • 8.59.1.4 Chondrocytes
        • 8.59.1.5 Urothelial Cells
        • 8.59.1.6 Karoskin
        • 8.59.1.7 Karoderm
        • 8.59.1.8 Cell Bank
      • 8.59.2 Karocell's Research and Development
    • 8.60 Kensey Nash Corporation
      • 8.60.1 Biomaterials from Kensey
      • 8.60.2 Kensey's Collagen Technology
      • 8.60.3 Porous Tissue Matrix Technology
      • 8.60.4 Kensey's Products
        • 8.60.4.1 The Angio-Seal Vascular Closure Device
        • 8.60.4.2 Vitoss Scaffold Foam
        • 8.60.4.3 OsseoFit Porous Tissue Matrix
        • 8.60.4.4 Epi-Guide Bioresorbable Barrier Matrix
    • 8.61 Kiadis Pharma, BV
    • 8.62 LifeCell
      • 8.62.1 AlloDerm Regenerative Tissue Matrix
      • 8.62.2 Strattice Reconstructive Tissue Matrix
      • 8.62.3 Cymetra Micronized AlloDerm Tissue
    • 8.63 MaxCyte, Inc
      • 8.63.1 Advantages of MaxCyte Platform System
      • 8.63.2 MaxCyte's Collaborations
      • 8.63.3 MaxCyte's Application in Immunotherapy
      • 8.63.4 MaxCyte's Application in Regenerative Medicine
      • 8.63.5 MaxCyte's Viral Vectors and Vaccines
      • 8.63.6 MaxCyte XTS Scalable Transfection System
    • 8.64 Mesoblast Ltd
      • 8.64.1 Mesoblast's Intervertebral Spinal Fusion
      • 8.64.2 Lumbar Fusion
      • 8.64.3 Cervical Fusion
      • 8.64.4 Mesoblast's Intervertebral Disc Repair and Regeneration
      • 8.64.5 Mesoblast's Product for Knee Osteoarthritis
      • 8.64.6 Mesoblast's Investment in Angioblast Systems, Inc
      • 8.64.7 Angioblast's Product Candidate for Congestive Heart Failure
      • 8.64.8 Angioblast's Product Candidate for Bone Marrow Transplantation
    • 8.65 NanoCor Therapeutics, Inc
      • 8.65.1 NanoCor's Products
    • 8.66 NeuralStem, Inc
      • 8.66.1 NeuralStem's Technology
      • 8.66.2 NeuralStem's Research and Programs
      • 8.66.3 NeuralStem's Intellectual Property
    • 8.67 NeuroNova AB
      • 8.67.1 NeroNova's Neurogenesis Qualifier-Technology
      • 8.67.2 The sNN0029
      • 8.67.3 The sNN0031
      • 8.67.4 NeuroNova's Investors
    • 8.68 Olympus Terumo Biomaterials Corporation
      • 8.68.1 OSferion 60
      • 8.68.2 Terudermis
      • 8.68.3 Teruplug
      • 8.68.4 Osferion
      • 8.68.5 Boneceram P
    • 8.69 Opexa Therapeutics, Inc
      • 8.69.1 Opexa's T-Cell Platform
      • 8.69.2 Opexa's Stem Cell Platform
    • 8.70 Organogenesis, Inc
      • 8.70.1 Products from Organogenesis
        • 8.70.1.1 Apligraf
        • 8.70.1.2 VCT01
        • 8.70.1.3 CelTx for Oral Soft Tissue Regeneration
        • 8.70.1.4 FortaGen
        • 8.70.1.5 FortaPerm
        • 8.70.1.6 BioSTAR
    • 8.71 Orthovita, Inc
      • 8.71.1 Orthovita's Products
        • 8.71.1.1 Vitoss
        • 8.71.1.2 Vitoss and Bone Defect Grafting
        • 8.71.1.3 Vitoss in Spinal Fusion and Grafting
        • 8.71.1.4 Vitoss and Trauma
        • 8.71.1.5 Vitomatrix and Dental, Periodontal, Oral and Craniomaxillofacial Defects
        • 8.71.1.6 Cortoss Bone Augmentation Material
        • 8.71.1.7 Cortoss and Vertebral Augmentation of VCFs
        • 8.71.1.8 Cortoss and Screw Augmentation
        • 8.71.1.9 Orthovita's Aliquot Delivery System
      • 8.71.2 Orthovita's Biosurgery Products
      • 8.71.3 Partnership with Kensey for Vitoss Foam
      • 8.71.4 Partnership with Angiotech for Vitagel and CellPaker
      • 8.71.5 Partnership with Medafor for Vitasure
      • 8.71.6 Orthovita's Business Performance
    • 8.72 Osiris Therapeutics, Inc
      • 8.72.1 Osiris' Partnerships
      • 8.72.2 Osiris' Technologies
      • 8.72.3 Prochymal
      • 8.72.4 Chondrogen
    • 8.73 Osteotech, Inc
      • 8.73.1 Osteotech's Products
    • 8.74 Pervasis Therapeutics, Inc
      • 8.74.1 Pervasis' Clinical Focus
      • 8.74.2 Power of Endothellium
      • 8.74.3 Therapeutic Applications of Pervasis' Products
        • 8.74.3.1 Arteriovenous (AV) Access for Hemodialysis
        • 8.74.3.2 Peripheral Arterial Disease
    • 8.75 Pleuron
      • 8.75.1 Pleuron's Technology
    • 8.76 Pluristem Therapeutics, Inc
      • 8.76.1 Pluristem's PluriX 3D Bioreactor
      • 8.76.2 Pluristem's PLacental eXpanded (PLX) Cells
      • 8.76.3 PLX-PAD for Peripheral Artery Disease
      • 8.76.4 PLX-IBD for Inflammatory Bowel Disease
      • 8.76.5 PLX-MS for Multiple Sclerosis
      • 8.76.6 PLX-STROKE for Ischemic Stroke
    • 8.77 RegeneRx
    • 8.78 ReNeuron Group plc
      • 8.78.1 ReNeuron's Platform Technologies
      • 8.78.2 ReNeuron's Cell Therapy Programs
      • 8.78.3 ReNeuron's ReN001 for Stroke
      • 8.78.4 ReNeuron's ReNcell Products
    • 8.79 Revivicor, Inc
      • 8.79.1 Revivicor's Xenografting Technology
      • 8.79.2 Revivicor's Islet Transplantation Technology
      • 8.79.3 Revivicor's Infectious Disease Platform Technologies
    • 8.80 Saneron CCEL Therapeutics, Inc
      • 8.80.1 Saneron's U-Cord-Cell Program
      • 8.80.2 Saneron's Sert-Cell Program
    • 8.81 Sangamo BioSciences, Inc
      • 8.81.1 Sangamo's ZFP Therapeutic Product Development Programs
      • 8.81.2 ZFP Therapeutic Pre-clinical Stage Programs
        • 8.81.2.1 Neuropathic Pain (Cancer Pain)
        • 8.81.2.2 Nerve Regeneration-Spinal Cord Injury (SCI) and Traumatic Brain Injury (TBI)
        • 8.81.2.3 Parkinson's Disease (PD)
        • 8.81.2.4 Stroke
        • 8.81.2.5 ZFP Therapeutic Research Programs
      • 8.81.3 Funding from Research Foundations
        • 8.81.3.1 The Juvenile Diabetes Research Foundation International
        • 8.81.3.2 The Michael J. Fox Foundation
        • 8.81.3.3 The Bill and Melinda Gates Foundation
      • 8.81.4 Sangamo's Research and Development Expenses
      • 8.81.5 Sangamo's Business Performance
    • 8.82 StemCells, Inc
      • 8.82.1 StemCell's Cellular Medicine Programs
      • 8.82.2 StemCells' Enabling Technologies Program
      • 8.82.3 StemCells' Patents, Proprietary Rights and Licenses
    • 8.83 Stem Cell Authority Ltd
      • 8.83.1 The "Miracle" Mesenchymal Stem Cell-Mirachymal Stem Cells
    • 8.84 Stem Cell Innovations (SCI)
      • 8.84.1 SCI's Research and Development
      • 8.84.2 SCI's Services
      • 8.84.3 PluriCells and Derivatives
      • 8.84.4 ACTIVTox
      • 8.84.5 PredictivTox
      • 8.84.6 Endogenous Protein Production
    • 8.85 Stem Cell Sciences KK
      • 8.85.1 SCS KK's Product/Service
        • 8.85.1.1 CultiCell Medium for Embryonic Stem Cells
        • 8.85.1.2 Contract/Sponsored Research on ES-derived Functional Cells
    • 8.86 SyntheMed, Inc
      • 8.86.1 Repel-CVAdhesion Barrier
      • 8.86.2 Resolve Adhesion Barrier Instillate
      • 8.86.3 Repel Adhesion Barrier
      • 8.86.4 SpineShield Adhesion Barrier Film
      • 8.86.5 Relieve Adhesion Barrier Gel
      • 8.86.6 SinusShield Adhesion Prevention Film
    • 8.87 t2cure GmbH
      • 8.87.1 BMCs in Regenerative Therapies
      • 8.87.2 t2cure's Product Development Pipeline
    • 8.88 Tengion
      • 8.88.1 Tengion's Pipeline Overview
    • 8.89 TiGenix
      • 8.89.1 ChondroCelect
      • 8.89.2 Chondromimetic
      • 8.89.3 TGX002
      • 8.89.4 TGX003
    • 8.90 Thermogenesis Corp
      • 8.90.1 Products from Thermogenesis
        • 8.90.1.1 AutoXpress Platform or AXP
        • 8.90.1.2 MarrowXpress
        • 8.90.1.3 BioArchive System
        • 8.90.1.4 Res-Q
        • 8.90.1.5 Thermoline
        • 8.90.1.6 CryoSeal Fibrin Sealant (CryoSeal) System
      • 8.90.2 Thermogenesis' Business Performance
  • Index Of Figures
    • Figure 2.1: Geographic Distribution of 73 TERM Firms in the Five Focus Countries, 2009
    • Figure 2.2: Geographic Distribution of the 15 TERM Firms in Germany, 2009
    • Figure 2.3: Geographic Distribution of the Five TERM Companies in the U.K., 2009
    • Figure 2.4: The Potential Uses of Embryonic Stem Cells
    • Figure 2.5: Cell Culture Products by Market Segment
    • Figure 2.6: Estimated Global Market for Cell and Tissue Analysis Products, 2008-2014
    • Figure 2.7: Growth in Size of Cell Therapy Industry, 2000-2008
    • Figure 2.8: Percent Break-up of Cell Therapy Companies by Product Type, 2008
    • Figure 2.9: Location of Primary Tissue Engineering Companies by Geography, 2008-2009
    • Figure 2.10: Breakdown of Primary Cell Therapy Products on Market by Geography, 2008-2009
    • Figure 2.11: The Geographical Distribution of Clinical Trials, 2008-2009
    • Figure 2.12: Implantation of a Hydrogel at the Site of an Injured Tissue
    • Figure 2.13: Implantation of CS-PEG Hydrogel
    • Figure 2.14: Implantation of CMP-PEG Scaffold
    • Figure 4.1: Global Market for Regenerative Medicine Products, 2008-2013
    • Figure 4.2: Estimated market for Regenerative Cell Therapy Products for Orthopedics, 2008-2012
    • Figure 4.3: Estimated U.S. Market for Regenerative Medicine Products, 2009-2014
    • Figure 4.4: Estimated U.S. Market for Bone Grafting/Bone Replacement, 2009-2014
    • Figure 4.5: Estimated U.S. Market for Bone Growth Stimulating Substances, 2009-2014
    • Figure 4.6: Estimated U.S. Market for Regenerative Products for Cartilage Repair, 2009-2014
    • Figure 4.7: Estimated Market for Stem cells, 2008-2012
    • Figure 4.8: Estimated Market for Cell Therapy Products in the U.S., 2009-2018
    • Figure 4.9: Estimated Global Market for Cord Blood Stem Cells, 2010-2015
    • Figure 4.10: Worldwide Growth of Public Cord Blood Banks, 2005-2009
    • Figure 4.11: Worldwide Growth of Private Cord Blood Banks, 2005-2009
    • Figure 5.1: Cell-based Business Models
    • Figure 5.2: Current Autologous Business Models
    • Figure 5.3: Current Allogeneic Business Models
    • Figure 7.1: CIRM's Grant Awards by Category, 2009
    • Figure 7.2: CIRM's Funding by Disease Application, 2009
    • Figure 7.3: CIRM's Funding by Disease Category
    • Figure 7.4: Estimated Increase in Worldwide Funding for RM Research, 2008-2018
    • Figure 8.1: Aastrom's Investment in Research and Development, 2007-2009
    • Figure 8.2: Aastrom's Business Performance, 2005-2009
    • Figure 8.3: ACT's Business Performance, 2008 and 2009
    • Figure 8.4: ACT's Investment in Research and Development, 2008 and 2009
    • Figure 8.5: Aranesp (Darbepoetin Alfa)'s Sales in the U.S. and International Market, 2007-2009
    • Figure 8.6: U.S. Market for Epogen, 2007-2009
    • Figure 8.7: Global Market for Neulasta, 2007-2009
    • Figure 8.8: Global Market for Enbrel (Etanercept), 2007-2009
    • Figure 8.9: Global Market for Sensipar (Cinacalcet), 2007-2009
    • Figure 8.10: Global Market for Vectibix (Panitumumab), 2007-2009
    • Figure 8.11: Global Market for Nplate (Romiplostim), 2007-2009
    • Figure 8.12: Amgen's Three Large Wholesale Customers, 2007-2009
    • Figure 8.13: Amgen's Overall U.S. and International Market, 2007-2008
    • Figure 8.14: Athersys' Investment and Development, 2007-2009
    • Figure 8.15: Athersys' Business Performance, 2005-2009
    • Figure 8.16: Current Capitalization of Cardio3's Investors, 2009
    • Figure 8.17: Celgene's Business Performance, 2005-2009
    • Figure 8.18: Curis' Business Performance, 2005-2009
    • Figure 8.19: Genzyme's Business Performance, 2005-2009
    • Figure 8.20: Genzyme's Percent of Revenue by Business Group, 2009
    • Figure 8.21: Geron's Business Performance, 2005-2009
    • Figure 8.22: Geron's Investment in Research and Development, 2005-2009
    • Figure 8.23: Integra's Investment in Research and Development, 2007-2009
    • Figure 8.24: Integra's Business Performance, 2005-2009
    • Figure 8.25: NeuroNova's Share Holders as of June, 2009
    • Figure 8.26: Orthovita's Business Performance, 2005-2009
    • Figure 8.27: Sangamo's Investment in Research and Development, 2007-2009
    • Figure 8.28: Sangamo's Business Performance, 2005-2009
  • Index Of Tables
    • Table 2.1: Number of TERM Companies Identified in the Five Focus Countries, 2009
    • Table 2.2: Number of TERM Companies Developing Stem Cells Seeded to Scaffolds, 2009
    • Table 2.3: Number of Firms with Focus on Skin, Cartilage, Bone and Urological Applications, 2009
    • Table 2.4: Number of Firms Focusing on Cardiovascular Applications, 2009
    • Table 2.5: Number of Firms with a Focus on Neurological Applications, 2009
    • Table 2.6: Number of Firms Focused on Pancreas, Liver and Kidney Applications, 2009
    • Table 2.7: Number of Companies Focused on Autologous and Allogeneic Products, 2009
    • Table 2.8: Geographic Distribution of 37 U.S. TIRM Firms, 2009
    • Table 2.9: Geographic Location of 11 out of 13 TERM Firms in Japan, 2009
    • Table 2.10: Geographic Distribution of the Three TERM Firms in Sweden, 2009
    • Table 2.11: Number of Patients Treated with Cell Therapeutics, 1988-2010
    • Table 2.12: Some Selected Suppliers of In vitro Test Kits and Their Products
    • Table 2.13: Suppliers of Cells and Tissues
    • Table 2.14: Selected Suppliers of Media and Reagents
    • Table 2.15: Selected Providers of Equipments in Stem Cell Research
    • Table 2.16: Selected Providers of Computer Software for Stem Cell Research
    • Table 2.17: Geographical Distribution of Stem Cell-related Tissue Engineering Companies, 2008
    • Table 2.18: Breakdown of Cell Therapy Firms by Country, 2008-2009
    • Table 2.19: Cell Therapy Products on the Market by Type and Application Area, 2008-2009
    • Table 2.20: Data on Sales and Application for Skin and Cartilage Products, 2006-2008
    • Table 2.21: Reagent Sales by Selected Stem Cell Companies, 2008
    • Table 2.22: Sales of Secondary Products, 2007
    • Table 2.23: Disease Focus of Clinical Trials, 2008-2009
    • Table 2.24: Stem Cell Products in Phase II/III Trials, 2008-2009
    • Table 2.25: Licensing Activities in Pharmaceutical and Cell Therapy Industries
    • Table 2.26: Investment Activity in Cell Therapy Sector
    • Table 2.27: Novel Partnership by Large Pharmaceuticals with Universities
    • Table 2.28: Cell Therapy Companies with Greater than Ten Million by Market Cap, 2008
    • Table 3.1: Regenerative Medicine Product Development Status, 2008
    • Table 3.2: Top Ten Regenerative Medicine Products, 2008
    • Table 3.3: Wound Healing Products
    • Table 4.1: Worldwide Estimates of Key Industry Parameters, 2007
    • Table 4.2: Potential U.S. Populations for Cell-based Therapies
    • Table 5.1: The Required Elements of a Manufacturing Facility
    • Table 5.2: Cell Therapy CMO Qualification Audit: Points to Investigate
    • Table 6.1: Diseases with Potential Applications for Regenerative Medicine
    • Table 7.1: Stem Cell Policies in North America
    • Table 7.2: Stem Cell Policies in South America
    • Table 7.3: Stem Cell Policies in Europe
    • Table 7.4: Stem Cell Policies in Asia/Oceania
    • Table 7.5: CIRM Funded Grants To-Date
    • Table 7.6: List of Upcoming Request for Applications (RFAs) Showing Commitments from Funding Partners
    • Table 7.7: Recipients of Funds from Connecticut Stem Cell Research Program, 2009
    • Table 7.8: Maryland Stem Cell Research Fund, 2008
    • Table 7.9: NJCST's Award of Grants for Stem Cell Research, 2008
    • Table 7.10: NYSTEM's IIRP Awards, 2008
    • Table 7.11: NIH Funding for Regenerative Medicine and Stem Cell Research, 2003-2009
    • Table 7.12: NIH Funding for Various Types of Stem Cell Research, 2004-2009
    • Table 8.1: Patents Owned by ACT
    • Table 8.2: Patents Owned by ACT's Subsidiary Mytogen, Inc
    • Table 8.3: Patents Licensed to ACT by the University of Massachusetts
    • Table 8.4: Alseres' Product Pipeline, 2009
    • Table 8.5: Amgen's Pipeline of Products
    • Table 8.6: Amgen's Approved Products
    • Table 8.7: AnGes' Current Pipeline Status, 2010
    • Table 8.8: Angioblast's Product Development Overview
    • Table 8.9: Angion's Product Pipeline
    • Table 8.10: Angion's Product Pipeline
    • Table 8.11: Arteriocyte's Product Pipeline
    • Table 8.12: Developmental Status of Athersys' Key Programs, 2010
    • Table 8.13: Biohearts Pipeline Product Candidates
    • Table 8.14: BioLines Product Pipeline, 2010
    • Table 8.15: BioMimetic's Current Product Candidates and Target Indications
    • Table 8.16: BioMimetic's Clinical Studies
    • Table 8.17: BioMimetic's Investment in Research and Development, 2005-2009
    • Table 8.18: BrainStorm's Intellectual Property
    • Table 8.19: Cardio3's Promising Product Pipeline
    • Table 8.20: Cellerix's Product Pipeline
    • Table 8.21: Celgene's Leading Product Candidates
    • Table 8.22: Private Cord Blood Banking vs. Public Donation
    • Table 8.23: Curis' Current Research and Development Programs and Their Status
    • Table 8.24: Curis' Revenues from Research and Development, 2008 and 2009
    • Table 8.25: Regulatory Status of Celution System
    • Table 8.26: Regulatory Status of PureGraft and CelBrush
    • Table 8.27: Develogen's Pipeline Overview
    • Table 8.28: Epistem's Emerging Pipeline of Protein Therapeutics
    • Table 8.29: FivePrime's Product Pipeline
    • Table 8.30: FivePrime's Collaborations
    • Table 8.31: Gamidia's Pipeline Products
    • Table 8.32: Genzyme's Pipeline of Products
    • Table 8.33: Cancer Therapeutics and Diagnostic Products being Developed by Geron
    • Table 8.34: The hESC-derived Product Candidates Developed by Geron and its Collaborators
    • Table 8.35: Geron's Patent Portfolio
    • Table 8.36: Hydra's Product Pipeline
    • Table 8.37: Intercytex' Product Pipeline
    • Table 8.38: Kiadis' Product Pipeline
    • Table 8.39: NeuralStem's Issued and Pending Patents
    • Table 8.40: NeuroNova's Product Pipeline
    • Table 8.41: Orthovita's Existing Orthobiologic and Biosurgery Products
    • Table 8.42: Orthovita's Biosurgery Products
    • Table 8.43: Osiris' Therapeutic Product Pipeline
    • Table 8.44: Pervasis' Product Pipeline
    • Table 8.45: RegeneRx's Product Development Pipeline
    • Table 8.46: Summary of Sangamo's Current Clinical Programs
    • Table 8.47: Current Status of StemCells' Therapeutic Product Development Programs
    • Table 8.48: StemCells' Cell Culture Products
    • Table 8.49: StemCells' Patents Covering Stem and Progenitor Cells and Research Tools
    • Table 8.50: t2cure's Product Development Pipeline
    • Table 8.51: Tengion's Product Candidates Pipeline
    • Table 8.52: Thermogenisis' Business Performance by Geographic Area, 2007-2009